Regeneron CEO Says Company Will Provide 300,000 Doses of Covid Treatment for US by January

Regeneron Chief Executive Dr. Leonard Schleifer has said to CNBC that the company will be provoding 300,000 doses of its Covid-19 antibody treatment for the United States by early January.

According to Schleifer, the company will be able to supply 100,000 doses a month after that point.

It was this past weekend that the Food and Drug Administration on Saturday granted an emergency use authorization for the company’s antibody treatment dubbed REGN-COV2. The therapy had been given to President Donald Trump when he contracted the coronavirus in October.

Regeneron had been given $450 million in funding from the Trump Administration in Operation Warp Speed to support the manufacturing of the drug.

Speaking to CNBC’s “Squawk Box” on Monday, Schleifer said the company has 80,000 doses of its antibody treatment immediately ready for distribution. The federal government will be responsible for allocating the doses to the states “proportion to the need and amount of Covid.”

Regeneron is also conducting experiments to determine whether the dosage can be cut in half, which would eventually double the amount of available doses to 200,000 every month if proven effective, he said.

“We hope to have millions of doses available. Now still, that might not be enough,” Schleifer added.

The CEO believes hopes an eventual coronavirus vaccine would bring down the number of cases.

“I’m hopeful that will really bring down the number of cases and that those people that still get it, because they didn’t either respond to the vaccine, or they didn’t access the vaccine or didn’t want the vaccine, that there will be this monoclonal cocktail of ours available for treatment,” he said.

“I think as we get more experience, we’ll have a more efficient administration supply chain,” he told CNBC. “We don’t want to commingle, if you will, somebody who’s already infected, but we do want to treat these people, because you can reduce the risk of hospitalizations.”

Disclaimer: We have no position in any of the companies mentioned and have not been compensated for this article.